Close
Close
Treatment Database
saracatinib
Trade Name not avaiable
Orphan Indication Idiopathic pulmonary fibrosis
USA Market Approval
USA Designation Date 11-03-2019
Sponsor AstraZeneca Pharmaceuticals, LP
Emerging Innovations, AstraZeneca, R&D
Boston, 35 Gatehouse Drive
Waltham, Massachusetts, 02451
More about Idiopathic pulmonary fibrosis
Free Newsletter
Related Videos
by Abidemi Uruejoma
407 views